Ludwig Institute for Cancer Research Limited

Francis Brasseur

Thierry R Boon-Falleur

Christophe Lurquin

Aline Van Pel

Nicolas Van Baren

Etienne De Plaen

Pierre Van Der Bruggen

Bernard Lethe

Etienne DePlaen

Daniele Godelaine

Charles DeSmet

Lan-Qing Huang

Javier Carrasco

Benoit Van Den Eynde

Thierry Boon

Donata Rimoldi

Jean-Jacques Patard

P Weynants

M Marchand

Marie Marchand

Patrick Weynants

Leonora Heidecker

Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumour rejection antigens

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x3b2;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

MAGE-C2 antigenic peptides and uses thereof

Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumor rejection antigens

Mage C2 antigenic peptides and uses thereof

The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

Mage-A12 antigenic peptides and uses thereof

The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.

Isolated protein molecules which are members of the MAGE-B family

Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches to multiple myeloma are also disclosed.

Methods for diagnosing multiple myeloma by determining rejection antigen precursors

A correlation between expression of tumor rejection antigen precursor MAGE-10 and cancer has been discovered. The invention is a method for determining presence of cancer in a sample by determining expression of MAGE-10. This determination can be made via, e.g., an immunoassay, an oligonucleotide hybridization assay, or via other standard methodologies.

Method for determining cancer by determining expression of MAGE-10

Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors

Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches of multiple myeloma are also disclosed.

Method for determining regression or progression of multiple myeloma

The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MASGE genes.

Isolated nucleic acid molecules which are members of the MAGE-B family

Method for determining multiple myeloma by assaying for expression of

A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.

Method for determining lung adenocarcinomas by assaying for one or more

The invention involves assaying for possible presence of certain cancers, by screening a sample for a member of the MAGE-Xp family of genes. These cancers include testicular seminoma, non-small call lung carcinoma, melanoma, breast cancer, sarcoma, and leukemia.

Growing community of inventors

Brussels, Belgium

Francis Brasseur